### **Advanced Chemical Industries Limited**

3rd Quarter ended Report 2019 - 2020 for the nine months period ended on 31 March 2020

### Advanced Chemical Industries Limited Statement of financial position Unaudited

	Nete	As at	Figures in '000' Taka As at
	Note	31 March 2020	30 June 2019
Assets			Restated*
Property, plant and equipment	2	10,518,560	9,891,774
Right-of-use assets	1 200	569,029	562,499
Investments	3	2,819,735	2,644,630
Intangible assets		4,040	268
Biological assets		8,268	-
Deferred tax assets		273,681	86,567
Non-current assets		14,193,312	13,185,737
Inventories	4	5,469,441	5,476,073
Trade receivables	5	3,988,152	5,158,496
Other receivables	5	542,209	279,085
Inter-company receivables	6	18,640,473	14,925,701
Advances, deposits and prepayments	7	2,597,919	2,177,760
Cash and cash equivalents	1	921,194	992,956
Current assets		32,159,388	29,010,071
Total assets		46,352,701	42,195,808
			, , , , , , , , , , , , , , , , , , , ,
Equity		572 720	100 005
Share capital		573,730	498,895
Share premium Reserves		402,310	402,310
		3,523,324	3,633,117
Retained earnings  Total equity		10,427,206	9,788,136
1 otai equity		14,926,569	14,322,458
Liabilities			
Employee benefits	8	1,039,592	941,229
Long term borrowings	9	576,950	567,628
Non-current portion of lease liability		524,765	493,749
Non-current liabilities		2,141,307	2,002,606
Bank overdraft		3,155,670	2,633,244
Loans and borrowings	10	13,659,805	12,827,625
Current portion of lease liability		137,654	150,925
Trade payables		1,697,056	1,199,383
Inter-company payables	11	5,016,677	4,549,730
Other payables	12	3,256,954	2,755,802
Current tax liability		2,361,007	1,754,034
Current liabilities		29,284,824	25,870,743
Total liabilities		31,426,132	27,873,350
Total equity and liabilities		46,352,701	42,195,808
Net asset value (NAV) per share		260.17	249.64

<sup>\*</sup>See Note 20-The Group has applied IFRS 16 using retrospective approach. Therefore, comparative information has been restated.

**Managing Director** 

Director

1

Chief Financial Officer

Company Secretary

### Advanced Chemical Industries Limited Statement of profit or loss Unaudited

				Figures	in '000' Taka
		For the period up	to 3rd Quarter	For the 3r	d Quarter
ø i	Note	July 2019 to March 2020	July 2018 to March 2019	January to March 2020	January to March 2019
			Restated*	_	Restated*
Revenue	13	17,257,345	16,325,901	5,971,519	5,112,159
Cost of sales	14	(8,877,019)	(9,002,365)	(3,050,569)	(2,872,556)
Gross profit	250	8,380,326	7,323,536	2,920,950	2,239,604
Administrative, selling and distribution expenses	15	(6,580,598)	(5,940,574)	(2,205,456)	(2,054,812)
Other income		476,212	129,223	14,552	32,054
Operating profit		2,275,940	1,512,185	730,046	216,846
Net finance costs		(544,511)	(556,415)	(194,876)	(192,242)
Profit before contribution to WPPF		1,731,429	955,770	535,170	24,603
Contribution to WPPF		(86,571)	(48,685)	(26,758)	(1,482)
Profit before tax		1,644,858	907,085	508,411	23,121
Income tax expense		(432,059)	(236,761)	(133,534)	(6,801)
Profit after tax		1,212,798	670,324	374,877	16,320
Earnings per share					
Basic earnings per share (EPS)		21.14	11.68	6.53	0.28

**Managing Director** 

Director

**Chief Financial Officer** 

Company Secretary

### Advanced Chemical Industries Limited Statement of profit or loss and other comprehensive income Unaudited

	For the period up	to 3rd Quarter	Figures in '000' Taka For the 3rd Quarter		
	July 2019 to March 2020	July 2018 to March 2019	January to March 2020	January to March 2019	
		Restated*		Restated*	
Profit after tax	1,212,798	670,324	374,877	16,320	
Other comprehensive income:					
Change in fair value of FVOCI/available-for-sale financial assets	(121,992)	101,294	(38,186)	(22,934)	
Income tax on FVOCI/available-for-sale financial assets	12,199	(10,129)	3,818	2,294	
Other comprehensive income, net of tax	(109,793)	91,165	(34,368)	(20,640)	
Total comprehensive income	1,103,005	761,489	340,509	(4,321)	

### Advanced Chemical Industries Limited Statement of changes in equity Unaudited

Figures in '000' Taka

	Share capital	Share premium	F Capital reserve	FVOCI reserve	to 3rd Quarter fr Revaluation surplus	om July 2019 to Retained earnings	March 2020 Total equity
Restated Balance at 1 July 2019	498,895	402,310	1,671	555,904	3,075,541	9,788,136	14,322,458
Total comprehensive income							
Profit after tax	-	-	-	-	-	1,212,798	1,212,798
Other comprehensive income-net of tax	-	-	-	(109,793)	-	-	(109,793)
Total comprehensive income	-	-	-	(109,793)	-	1,212,798	1,103,005
Transaction with owners of the Company							
Share premium	-	-	-	-	-	-	-
Stock dividend for 2018-19	74,834	-	-	-	-	(74,834)	-
Cash dividend for 2018-19	-	-	-	-	-	(498,895)	(498,895)
Total transactions with owners of the Company	74,834	-	-	-	-	(573,730)	(498,895)
Balance at 31 March 2020	573,730	402,310	1,671	446,111	3,075,541	10,427,206	14,926,569

			I	For the period up	to 3rd Quarter fr	om July 2018 to	March 2019
	Share capital	Share premium	Capital reserve	Available for sale reserve	Revaluation surplus	Retained earnings	Total equity
Restated Balance at 1 July 2018	482,024	402,310	1,671	466,460	3,075,541	9,827,892	14,255,899
Total comprehensive income							
Profit after tax	_	-	-	-	-	670,324	670,324
Other comprehensive income-net of tax	-	-	-	91,165	-	-	91,165
Total comprehensive income	-	-	-	91,165	-	670,324	761,489
Transaction with owners of the Company							
Share premium	_	-	-	-	-	-	-
Stock dividend for 2017-18	16,871	-	-	-	-	(16,871)	-
Cash dividend for 2017-18	-	-	-	-	-	(554,328)	(554,328)
Total transactions with owners of the company	16,871	-	-	-	=	(571,199)	(554,328)
Balance at 31 March 2019	498,895	402,310	1,671	557,625	3,075,541	9,927,017	14,463,060

### Advanced Chemical Industries Limited Statement of cash flows Unaudited

Finance costs paid (461,968) (480,327   Income tax paid (370,194) (357,360   (872,540) (898,460   Net cash from / (used in) operating activities* 16 2,922,014 459,933    Cash flows from investing activities  Acquisition of property, plant and equipment (183,140) (61,405   Sale proceeds from property, plant and equipment (183,140) (61,405   Sale proceeds from property, plant and equipment (183,140) (61,405   Sale proceeds of Brands (182,756) (961,164   Sale proceeds of Brands (194,000   Sale proceeds (194,0			Figures in '000' T				
to         to         to           Restated**           Cash flows from operating activities           Cash receipts from customers and others         17,764,137         15,933,171           Cash paid to suppliers and employees         (13,969,583)         (14,574,778           Cash generated from operating activities         3,794,554         1,358,393           Paid to WPPF         (40,378)         (60,773           Finance costs paid         (461,968)         (480,327           Income tax paid         (370,194)         (357,360           Net cash from/ (used in) operating activities*         (872,540)         (898,466           Net cash from from roseting activities         46 2,922,014         459,933           Cash flows from investing activities         5 2,922,014         459,933           Cash flows from investing activities         6 2,922,014         459,933           Cash flows from property, plant and equipment         (183,140)         (61,405           Sale proceeds from property, plant and equipment         5,429         767           Sale proceeds of Brands         -         540,300           Investment         (297,097)         -           Net cash (used) in investing activities         (916,777)							
Cash flows from operating activities           Cash paid to suppliers and employees         17,764,137         15,933,171           Cash paid to suppliers and employees         (13,969,583)         (14,574,778           Cash generated from operating activities         3,794,554         1,358,393           Paid to WPPF         (40,378)         (60,772           Finance costs paid         (461,968)         (480,327           Income tax paid         (370,194)         (357,360           Net cash from / (used in) operating activities*         16         2,922,014         459,933           Cash flows from investing activities         (872,540)         (898,460           Net cash from / (used in) operating activities*         16         2,922,014         459,933           Cash flows from investing activities         (828,756)         (891,164           Sale proceeds from property, plant and equipment         (183,140)         (61,405           Sale proceeds from property, plant and equipment         5,429         767           Sale proceeds from property, plant and equipment         (297,097)         -           Sale proceeds from property, plant and equipment         (30,300,986         (30,300,986           Investment         (297,097)         -         -           Sale proceeds fro			<u> </u>	•			
Cash flows from operating activities           Cash receipts from customers and others         17,764,137         15,933,171           Cash paid to suppliers and employees         (13,969,583)         (14,574,778           Cash generated from operating activities         3,794,554         1,358,393           Paid to WPPF         (40,378)         (60,773           Finance costs paid         (461,968)         (480,327           Income tax paid         (370,194)         (357,366           Restacted         (872,540)         (898,466           Net cash from / (used in) operating activities*         16         2,922,014         459,933           Cash flows from investing activities         Acquisition of property, plant and equipment         (183,140)         (61,405           Payments for capital work in progress         (828,756)         (961,164           Sale proceeds from property, plant and equipment         5,429         767           Sale proceeds of Brands         -         540,300           Dividend received         386,787         87,087           Sale proceeds from property, plant and equipment         (397,097)         -           Net cash (used) in investing activities         (297,097)         -           Net cash (used) in investing activities         (31,040,098 <th></th> <th></th> <th></th> <th></th>							
Cash flows from operating activities           Cash receipts from customers and others         17,764,137         15,933,171           Cash paid to suppliers and employees         (13,969,583)         (14,574,778           Cash generated from operating activities         3,794,554         1,358,393           Paid to WPPF         (40,378)         (60,773           Finance costs paid         (461,968)         (480,327           Income tax paid         (370,194)         (357,366           Net cash from / (used in) operating activities*         16         2,922,014         459,932           Cash flows from investing activities         459,932         459,932           Cash flows from investing activities         6         2,922,014         459,932           Cash flows from investing activities         6         2,922,014         459,932           Cash flows from investing activities         (828,756)         (961,164           Sale proceeds from property, plant and equipment         5,429         767           Sale proceeds from property, plant and equipment         5,429         767           Sale proceeds from property, plant and equipment         (91,777)         394,415           Cash flows from financing activities         (916,777)         (394,415           Dividend paid <th></th> <th></th> <th>March 2020</th> <th></th>			March 2020				
Cash receipts from customers and others         17,764,137         15,933,171           Cash paid to suppliers and employees         (13,969,583)         (14,574,778           Cash generated from operating activities         3,794,554         1,358,393           Paid to WPPF         (40,378)         (60,773           Finance costs paid         (461,968)         (480,327           Income tax paid         (370,194)         (357,360           Net cash from / (used in) operating activities*         16         2,922,014         459,933           Cash flows from investing activities         Cash flows from investing activities         (828,756)         (961,164           Acquisition of property, plant and equipment         (183,140)         (61,405           Sale proceeds from property, plant and equipment         5,429         767           Sale proceeds of Brands         -         540,300           Dividend received         386,787         87,087           Investment         (297,097)         -           Net cash (used) in investing activities         (916,777)         (394,415           Cash flows from financing activities         (916,777)         (394,415           Cash flows from financing activities         (129,632)         (101,822           Payment for lease liabilities				Restated*			
Cash paid to suppliers and employees         (13,969,583)         (14,574,778           Cash generated from operating activities         3,794,554         1,358,393           Paid to WPPF         (40,378)         (60,772           Finance costs paid         (461,968)         (480,327           Income tax paid         (370,194)         (357,360           Net cash from / (used in) operating activities*         16         2,922,014         459,932           Cash flows from investing activities         Acquisition of property, plant and equipment         (183,140)         (61,405           Payments for capital work in progress         (828,756)         (961,164         5429         767           Sale proceeds from property, plant and equipment         5,429         767         767           Sale proceeds of Brands         -         540,907         -           Investment         (297,097)         -         -           Investment         (297,097)         -         -           Net cash (used) in investing activities         (916,777)         (394,415           Cash flows from financing activities         (916,777)         (394,415           Cash flows from financing activities         (12,9632)         (101,822           Payment for lease liabilities         (12,9632)			15 5 4 4 2 5	17.000.171			
Cash generated from operating activities         3,794,554         1,358,393           Paid to WPPF         (40,378)         (60,773           Finance costs paid         (461,968)         (480,327           Income tax paid         (370,194)         (357,360           Net cash from / (used in) operating activities*         16         2,922,014         459,933           Cash flows from investing activities           Acquisition of property, plant and equipment         (183,140)         (61,405           Payments for capital work in progress         (828,756)         (961,164           Sale proceeds from property, plant and equipment         5,429         767           Sale proceeds of Brands         -         540,300           Dividend received         386,787         87,087           Investment         (297,097)         -           Net cash (used) in investing activities         (916,777)         (394,415           Cash flows from financing activities         (916,777)         (394,415           Cash flows from financing activities         (129,632)         (101,822           Inter-company debts received/(paid)         (3,247,824)         (3,080,986           Dividend paid         (63,474)         (542,250           Payment for lease liabilities	_			· ·			
Paid to WPPF Finance costs paid Income tax pai	· · · · · · · · · · · · · · · · · · ·						
Finance costs paid (461,968) (480,327   Income tax paid (370,194) (357,360   (872,540) (898,400) (898,400) (898,400) (898,400) (898,400) (898,400) (898,400)	Cash generated from operating activities		3,794,554	1,358,393			
Income tax paid	Paid to WPPF		(40,378)	(60,773)			
Net cash from / (used in) operating activities*         16         2,922,014         459,933           Cash flows from investing activities         Acquisition of property, plant and equipment         (183,140)         (61,405           Payments for capital work in progress         (828,756)         (961,164           Sale proceeds from property, plant and equipment         5,429         767           Sale proceeds of Brands         -         540,300           Dividend received         386,787         87,007           Investment         (297,097)         -           Net cash (used) in investing activities         (916,777)         (394,415           Cash flows from financing activities         (916,777)         (394,415           Cash flows from financing activities         (129,632)         (101,822           Inter-company debts received/(paid)         (3,247,824)         (3,080,986           Dividend paid         (63,474)         (542,250           Payment for lease liabilities         (129,632)         (101,822           Short-term bank loan received/(paid)         832,181         2,340,260           Long-term bank loan received/(paid)         9,322         575,933           Net cash (used)/from financing activities         (2,599,427)         (808,865           Cash and cash e	Finance costs paid		(461,968)	(480,327)			
Net cash from / (used in) operating activities*         16         2,922,014         459,933           Cash flows from investing activities         32,922,014         459,933           Acquisition of property, plant and equipment of property, plant and equipment of capital work in progress (828,756)         (961,164)           Sale proceeds from property, plant and equipment of S,429         767           Sale proceeds of Brands         -         540,300           Dividend received         386,787         87,087           Investment         (297,097)         -           Net cash (used) in investing activities         (916,777)         (394,415           Cash flows from financing activities         (3,247,824)         (3,080,986)           Inter-company debts received/(paid)         (3,247,824)         (3,080,986)           Dividend paid         (63,474)         (542,250)           Payment for lease liabilities         (129,632)         (101,822)           Short-term bank loan received/(paid)         832,181         2,340,260           Long-term bank loan received/(paid)         9,322         575,933           Net cash (used)/from financing activities         (2,599,427)         (808,865)           Net increase / (decrease) in cash and cash equivalents         (594,188)         (743,348)           Cash and c	Income tax paid		(370,194)	(357,360)			
Cash flows from investing activities           Acquisition of property, plant and equipment         (183,140)         (61,405)           Payments for capital work in progress         (828,756)         (961,164)           Sale proceeds from property, plant and equipment         5,429         767           Sale proceeds of Brands         -         540,300           Dividend received         386,787         87,087           Investment         (297,097)         -           Net cash (used) in investing activities         (916,777)         (394,415)           Cash flows from financing activities         (101,822)         (3,080,986)           Dividend paid         (63,474)         (542,250)           Payment for lease liabilities         (129,632)         (101,822)           Short-term bank loan received/(paid)         832,181         2,340,260           Long-term bank loan received/(paid)         9,322         575,933           Net cash (used)/from financing activities         (2,599,427)         (808,865)           Net increase / (decrease) in cash and cash equivalents         (594,188)         (743,348)           Cash and cash equivalents at 1 July         (1,640,288)         (1,293,505)           Cash and cash equivalents at 31 March         (2,234,476)         (2,036,853)	•		(872,540)	(898,460)			
Cash flows from investing activities           Acquisition of property, plant and equipment         (183,140)         (61,405)           Payments for capital work in progress         (828,756)         (961,164)           Sale proceeds from property, plant and equipment         5,429         767           Sale proceeds of Brands         -         540,300           Dividend received         386,787         87,087           Investment         (297,097)         -           Net cash (used) in investing activities         (916,777)         (394,415)           Cash flows from financing activities         (101,822)         (3,080,986)           Dividend paid         (63,474)         (542,250)           Payment for lease liabilities         (129,632)         (101,822)           Short-term bank loan received/(paid)         832,181         2,340,260           Long-term bank loan received/(paid)         9,322         575,933           Net cash (used)/from financing activities         (2,599,427)         (808,865)           Net increase / (decrease) in cash and cash equivalents         (594,188)         (743,348)           Cash and cash equivalents at 1 July         (1,640,288)         (1,293,505)           Cash and cash equivalents at 31 March         (2,234,476)         (2,036,853)	Net cash from / (used in) operating activities*	16		459,933			
Payments for capital work in progress       (828,756)       (961,164)         Sale proceeds from property, plant and equipment       5,429       767         Sale proceeds of Brands       -       540,300         Dividend received       386,787       87,087         Investment       (297,097)       -         Net cash (used) in investing activities       (916,777)       (394,415)         Cash flows from financing activities       (916,777)       (394,415)         Cash flows from financing activities       (101,822)       (3,080,986)         Dividend paid       (63,474)       (542,250)         Payment for lease liabilities       (129,632)       (101,822)         Short-term bank loan received/(paid)       832,181       2,340,260         Long-term bank loan received/(paid)       9,322       575,933         Net cash (used)/from financing activities       (2,599,427)       (808,865)         Net increase / (decrease) in cash and cash equivalents       (594,188)       (743,348)         Cash and cash equivalents at 1 July       (1,640,288)       (1,293,505)         Cash and cash equivalents at 31 March       (2,234,476)       (2,036,853)         Closing balance represents       (2,234,476)       (2,897,084)         Cash and cash equivalents       (3,	9						
Sale proceeds from property, plant and equipment       5,429       767         Sale proceeds of Brands       -       540,300         Dividend received       386,787       87,087         Investment       (297,097)       -         Net cash (used) in investing activities       (916,777)       (394,415         Cash flows from financing activities       (542,250)         Inter-company debts received/(paid)       (3,247,824)       (3,080,986)         Dividend paid       (63,474)       (542,250)         Payment for lease liabilities       (129,632)       (101,822)         Short-term bank loan received/(paid)       832,181       2,340,260         Long-term bank loan received/(paid)       9,322       575,933         Net cash (used)/from financing activities       (2,599,427)       (808,865         Net increase / (decrease) in cash and cash equivalents       (594,188)       (743,348)         Cash and cash equivalents at 1 July       (1,640,288)       (1,293,505)         Cash and cash equivalents at 31 March       (2,234,476)       (2,036,853)         Closing balance represents         Cash and cash equivalents       921,194       860,231         Bank overdraft       (3,155,670)       (2,897,084)         Closing balance represents				(61,405)			
Sale proceeds of Brands         -         540,300           Dividend received         386,787         87,087           Investment         (297,097)         -           Net cash (used) in investing activities         (916,777)         (394,415           Cash flows from financing activities         (196,777)         (394,415           Inter-company debts received/(paid)         (3,247,824)         (3,080,986           Dividend paid         (63,474)         (542,250           Payment for lease liabilities         (129,632)         (101,822           Short-term bank loan received/(paid)         832,181         2,340,260           Long-term bank loan received/(paid)         9,322         575,933           Net cash (used)/from financing activities         (2,599,427)         (808,865           Net increase / (decrease) in cash and cash equivalents         (594,188)         (743,348           Cash and cash equivalents at 1 July         (1,640,288)         (1,293,505           Cash and cash equivalents at 31 March         (2,234,476)         (2,036,853           Closing balance represents         (2,234,476)         (2,897,084           Cash and cash equivalents         (3,155,670)         (2,897,084           Bank overdraft         (3,155,670)         (2,897,084	, , , , , , , , , , , , , , , , , , , ,			(961,164)			
Dividend received       386,787       87,087         Investment       (297,097)       -         Net cash (used) in investing activities       (916,777)       (394,415         Cash flows from financing activities       Inter-company debts received/(paid)       (3,247,824)       (3,080,986         Dividend paid       (63,474)       (542,250         Payment for lease liabilities       (129,632)       (101,822         Short-term bank loan received/(paid)       832,181       2,340,260         Long-term bank loan received/(paid)       9,322       575,933         Net cash (used)/from financing activities       (2,599,427)       (808,865         Net increase / (decrease) in cash and cash equivalents       (594,188)       (743,348         Cash and cash equivalents at 1 July       (1,640,288)       (1,293,505         Cash and cash equivalents at 31 March       (2,234,476)       (2,036,853         Closing balance represents         Cash and cash equivalents       921,194       860,231         Bank overdraft       (3,155,670)       (2,897,084         (2,234,476)       (2,036,853			5,429	767			
Investment	•		-	540,300			
Net cash (used) in investing activities         (916,777)         (394,415)           Cash flows from financing activities         (3,247,824)         (3,080,986)           Inter-company debts received/(paid)         (63,474)         (542,250)           Payment for lease liabilities         (129,632)         (101,822)           Short-term bank loan received/(paid)         832,181         2,340,260           Long-term bank loan received/(paid)         9,322         575,933           Net cash (used)/from financing activities         (2,599,427)         (808,865)           Net increase / (decrease) in cash and cash equivalents         (594,188)         (743,348)           Cash and cash equivalents at 1 July         (1,640,288)         (1,293,505)           Cash and cash equivalents at 31 March         (2,234,476)         (2,036,853)           Closing balance represents         (2,194,476)         (2,897,084)           Cash and cash equivalents         921,194         860,231           Bank overdraft         (3,155,670)         (2,897,084)           (2,234,476)         (2,936,853)	Dividend received		•	87,087			
Cash flows from financing activities         Inter-company debts received/(paid)       (3,247,824)       (3,080,986)         Dividend paid       (63,474)       (542,250)         Payment for lease liabilities       (129,632)       (101,822)         Short-term bank loan received/(paid)       832,181       2,340,260         Long-term bank loan received/(paid)       9,322       575,933         Net cash (used)/from financing activities       (2,599,427)       (808,865)         Net increase / (decrease) in cash and cash equivalents       (594,188)       (743,348)         Cash and cash equivalents at 1 July       (1,640,288)       (1,293,505)         Cash and cash equivalents at 31 March       (2,234,476)       (2,036,853)         Closing balance represents       921,194       860,231         Bank overdraft       (3,155,670)       (2,897,084)         (2,234,476)       (2,036,853)				-			
Inter-company debts received/(paid)       (3,247,824)       (3,080,986         Dividend paid       (63,474)       (542,250         Payment for lease liabilities       (129,632)       (101,822         Short-term bank loan received/(paid)       832,181       2,340,260         Long-term bank loan received/(paid)       9,322       575,933         Net cash (used)/from financing activities       (2,599,427)       (808,865         Net increase / (decrease) in cash and cash equivalents       (594,188)       (743,348         Cash and cash equivalents at 1 July       (1,640,288)       (1,293,505         Cash and cash equivalents at 31 March       (2,234,476)       (2,036,853         Closing balance represents       921,194       860,231         Bank overdraft       (3,155,670)       (2,897,084         (2,234,476)       (2,234,476)       (2,036,853	Net cash (used) in investing activities		(916,777)	(394,415)			
Dividend paid       (63,474)       (542,250         Payment for lease liabilities       (129,632)       (101,822         Short-term bank loan received/(paid)       832,181       2,340,260         Long-term bank loan received/(paid)       9,322       575,933         Net cash (used)/from financing activities       (2,599,427)       (808,865         Net increase / (decrease) in cash and cash equivalents       (594,188)       (743,348         Cash and cash equivalents at 1 July       (1,640,288)       (1,293,505         Cash and cash equivalents at 31 March       (2,234,476)       (2,036,853         Closing balance represents       921,194       860,231         Bank overdraft       (3,155,670)       (2,897,084         (2,234,476)       (2,234,476)       (2,036,853	Cash flows from financing activities						
Payment for lease liabilities       (129,632)       (101,822         Short-term bank loan received/(paid)       832,181       2,340,260         Long-term bank loan received/(paid)       9,322       575,933         Net cash (used)/from financing activities       (2,599,427)       (808,865         Net increase / (decrease) in cash and cash equivalents       (594,188)       (743,348         Cash and cash equivalents at 1 July       (1,640,288)       (1,293,505         Cash and cash equivalents at 31 March       (2,234,476)       (2,036,853         Closing balance represents       921,194       860,231         Bank overdraft       (3,155,670)       (2,897,084         (2,234,476)       (2,036,853	Inter-company debts received/(paid)		(3,247,824)	(3,080,986)			
Short-term bank loan received/(paid)       832,181       2,340,260         Long-term bank loan received/(paid)       9,322       575,933         Net cash (used)/from financing activities       (2,599,427)       (808,865         Net increase / (decrease) in cash and cash equivalents       (594,188)       (743,348         Cash and cash equivalents at 1 July       (1,640,288)       (1,293,505         Cash and cash equivalents at 31 March       (2,234,476)       (2,036,853         Closing balance represents       921,194       860,231         Bank overdraft       (3,155,670)       (2,897,084         (2,234,476)       (2,234,476)       (2,036,853	Dividend paid		(63,474)	(542,250)			
Long-term bank loan received/(paid)         9,322         575,933           Net cash (used)/from financing activities         (2,599,427)         (808,865)           Net increase / (decrease) in cash and cash equivalents         (594,188)         (743,348)           Cash and cash equivalents at 1 July         (1,640,288)         (1,293,505)           Cash and cash equivalents at 31 March         (2,234,476)         (2,036,853)           Closing balance represents         921,194         860,231           Bank overdraft         (3,155,670)         (2,897,084)           (2,234,476)         (2,036,853)	Payment for lease liabilities		(129,632)	(101,822)			
Net cash (used)/from financing activities         (2,599,427)         (808,865)           Net increase / (decrease) in cash and cash equivalents         (594,188)         (743,348)           Cash and cash equivalents at 1 July         (1,640,288)         (1,293,505)           Cash and cash equivalents at 31 March         (2,234,476)         (2,036,853)           Closing balance represents         921,194         860,231           Bank overdraft         (3,155,670)         (2,897,084)           (2,234,476)         (2,036,853)	Short-term bank loan received/(paid)		832,181	2,340,260			
Net increase / (decrease) in cash and cash equivalents       (594,188)       (743,348)         Cash and cash equivalents at 1 July       (1,640,288)       (1,293,505)         Cash and cash equivalents at 31 March       (2,234,476)       (2,036,853)         Closing balance represents       921,194       860,231         Bank overdraft       (3,155,670)       (2,897,084)         (2,234,476)       (2,036,853)	Long-term bank loan received/(paid)		9,322	575,933			
Cash and cash equivalents at 1 July       (1,640,288)       (1,293,505)         Cash and cash equivalents at 31 March       (2,234,476)       (2,036,853)         Closing balance represents       921,194       860,231         Bank overdraft       (3,155,670)       (2,897,084)         (2,234,476)       (2,036,853)	Net cash (used)/from financing activities		(2,599,427)	(808,865)			
Cash and cash equivalents at 1 July       (1,640,288)       (1,293,505)         Cash and cash equivalents at 31 March       (2,234,476)       (2,036,853)         Closing balance represents       921,194       860,231         Bank overdraft       (3,155,670)       (2,897,084)         (2,234,476)       (2,036,853)	Not increase / (decrease) in cash and cash equivalents		(504 199)	(7/12/2/18)			
Cash and cash equivalents at 31 March       (2,234,476)       (2,036,853)         Closing balance represents       921,194       860,231         Bank overdraft       (3,155,670)       (2,897,084)         (2,234,476)       (2,036,853)							
Closing balance represents         Cash and cash equivalents       921,194       860,231         Bank overdraft       (3,155,670)       (2,897,084)         (2,234,476)       (2,036,853)							
Cash and cash equivalents       921,194       860,231         Bank overdraft       (3,155,670)       (2,897,084)         (2,234,476)       (2,036,853)				\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \			
Bank overdraft (3,155,670) (2,897,084 (2,234,476) (2,036,853	<u>.</u>		021 104	Q60 221			
(2,234,476) (2,036,853	•		•				
	Dank overgran			(2,897,084) (2,036,853)			
	Net operating cash flows per share (NOCFPS)		50.93	8.02			

<sup>\*</sup>See Note 16 for reconciliation of net operating cash flow.

### Advanced Chemical Industries Limited Consolidated statement of financial position Unaudited

	Note	As at	As at
	Noto		1070 W. 1070 B. 1070 B.
	Note	31 March 2020	30 June 2019
Annata			Restated*
Assets Property, plant and equipment	2 (a)	26 220 007	25 570 740
Right-of-use assets	2 (a)	26,338,087	25,570,748
Equity-accounted investees		1,370,025	1,434,888
Other investments		1,510,847	1,304,391
Other investments Intangible assets		735,486	848,208
•		121,132	103,178
Biological assets Deferred tax assets		8,268	-
		375,660	20.261.412
Non-current assets		30,459,504	29,261,413
Inventories	4 (a)	14,939,055	13,560,089
Trade receivables	5 (a)	13,397,048	13,827,166
Other receivables	- (-)	857,457	509,582
Inter-company receivables	6 (a)	9,411	50,584
Advances, deposits and prepayments	7 (a)	7,864,583	5,683,575
Cash and cash equivalents	, (u)	2,910,654	2,319,988
Current assets		.39,978,209	35,950,984
Total assets		70,437,713	65,212,397
Equity			
Share capital		573,730	498,895
Share premium		402,310	402,310
Reserves		4,722,881	4,833,537
Retained earnings		2,268,201	3,845,275
Equity attributable to the owners of the company		7,967,122	9,580,018
Non-controlling interest		(559,083)	(351,284
Total equity		7,408,039	9,228,734
Liabilities		.,,	
Employee benefits	8 (a)	1,345,672	1,178,872
Long term borrowings	9 (a)	8,264,998	8,079,177
Non-current portion of lease liability	9 (a)	1,283,734	1,336,583
Deferred tax liabilities		1,203,734	75,515
Non-current liabilities		10,894,404	10,670,148
Bank overdraft	22.5	5,368,901	4,618,177
Loans and borrowings	10 (a)	29,785,761	27,263,917
Current portion of lease liability		395,019	399,987
Trade payables		5,301,281	4,338,091
Other payables	12 (a)	5,946,657	4,699,441
Current tax liability		5,337,652	3,993,902
Current liabilities		52,135,270	45,313,514
Total liabilities		63,029,674	55,983,662
		70,437,713	65,212,397
Total equity and liabilities		70,437,713	03,212,397

<sup>\*</sup>See Note 20-The Group has applied IFRS 16 using retrospective approach. Therefore, comparative information has been restated.

**Managing Director** 

Director

Chief Financial Officer

Company Secretary

### Advanced Chemical Industries Limited Consolidated statement of profit or loss Unaudited

Figures in '000' Taka

		For the period u	p to 3rd Quarter	For the 3r	d Quarter
7	Note	July 2019 to March 2020	July 2018 to March 2019	January to March 2020	January to March 2019
			Restated*		Restated*
Revenue	13 (a)	51,859,146	46,278,989	18,405,542	15,440,914
Cost of sales	14 (a)	(36,227,875)	(32,863,031)	(12,807,157)	(11,215,018)
Gross profit		15,631,271	13,415,958	5,598,385	4,225,896
Administrative, selling and distribution expenses	15 (a)	(12,641,582)	(10,815,314)	(4,401,898)	(3,751,373)
Other income / (loss)		206,162	255,718	74,195	181,625
Operating profit		3,195,851	2,856,361	1,270,682	656,149
Share of profit of equity accounted investees		209,033	81,031	38,744	31,770
Net finance costs		(3,525,661)	(2,404,711)	(1,296,496)	(833,529)
Profit before contribution to WPPF		(120,777)	532,681	12,930	(145,610)
Contribution to WPPF		(164,900)	(114,776)	(53,777)	(23,228)
Profit before tax		(285,676)	417,905	(40,847)	(168,838)
Income tax expense		(909,458)	(823,207)	(335,493)	(188,064)
Profit after tax		(1,195,134)	(405,302)	(376,340)	(356,901)
Profit attributable to:					
Equity holders of the company		(1,003,320)	(315,698)	(303,609)	(318,345)
Non-controlling interests		(191,815)	(89,604)	(72,731)	(38,556)
Profit after tax		(1,195,134)	(405,302)	(376,340)	(356,901)
Earnings per share					
Basic earnings per share (EPS)		(17.49)	(5.50)	(5.29)	(5.55)

Managing Director

Director

**Chief Financial Officer** 

## Advanced Chemical Industries Limited Consolidated statement of profit or loss and other comprehensive income Unaudited

	For the period u	p to 3rd Quarter	Figures For the 3r	in '000' Taka d Quarter
	July 2019 to March 2020	July 2018 to March 2019	January to March 2020	January to March 2019
		Restated*		Restated*
Profit after tax	(1,195,134)	(405,302)	(376,340)	(356,901)
Other comprehensive income:				
Foreign operations - foreign currency translation differences	(493)	-	(63)	-
Change in fair value of FVOCI/available-for-sale financial assets	(122,507)	101,047	(38,186)	(22,869)
Income tax on other comprehensive income	12,251	(10,105)	3,819	2,287
Other comprehensive income, net of tax	(110,750)	90,943	(34,430)	(20,582)
Total comprehensive income	(1,305,884)	(314,359)	(410,770)	(377,484)
Total comprehensive income attributable to:				
Equity holders of the Company				
Profit after tax	(1,003,320)	(315,698)	(303,609)	(318,345)
Other comprehensive income	(110,657)	90,971	(34,426)	(20,589)
	(1,113,976)	(224,727)	(338,035)	(338,934)
Non-controlling interest				
Profit after tax	(191,815)	(89,604)	(72,731)	(38,556)
Other comprehensive income	(93)	(28)	(4)	7
	(191,908)	(89,632)	(72,735)	(38,549)
Total comprehensive income	(1,305,884)	(314,359)	(410,770)	(377,484)

### Advanced Chemical Industries Limited Consolidated Statement of changes in equity Unaudited

Figures in '000' Taka
For the period up to 3rd Quarter from July 2019 to March 2020

_	Attributable to owner of the Company									
	Share capital	Share premium	Capital reserve	Translation reserve	FVOCI reserve	Revaluation reserve	Retained earnings	Total	Non-controlling Interests	Total equity
Restated Balance at 1 July 2019	498,895	402,310	1,671	(848)	554,781	4,277,934	3,845,275	9,580,018	(351,284)	9,228,734
Total comprehensive income										
Profit after tax	-	-	-	-	-	-	(1,003,320)	(1,003,320)	(191,815)	(1,195,134)
Other comprehensive income-net of tax	-		-	(458)	(110,198)	-	-	(110,656)	(93)	(110,749)
Total comprehensive income	-	-	-	(458)	(110,198)	-	(1,003,320)	(1,113,976)	(191,908)	(1,305,883)
Transaction with owners of the Company										
Share premium	-	-	-	-	-	-	-	-	-	-
Stock dividend for 2018-19	74,834	-	-	-	-	-	(74,834)	-	-	-
Cash dividend for 2018-19	-	-	-	-	-	-	(498,895)	(498,895)	(73,269)	(572,164)
Adjustment for transfer of shares in subsidiary	-	=	-	-	-	-	(25)	(25)	57,378	57,353
Total transactions with owners of the Company	74,834	-	-	-	-	-	(573,755)	(498,920)	(15,891)	(514,811)
Balance at 31 March 2020	573,730	402,310	1,671	(1,307)	444,583	4,277,934	2,268,201	7,967,122	(559,083)	7,408,039

### For the period up to 3rd Quarter from July 2018 to March 2019

_	Attributable to owner of the Company									
	Share	Share	Capital	Translation	Available for	Revaluation	Retained		Non-controlling	Total
	capital	premium	reserve	reserve	sale reserve	surplus	earnings	Total	Interests	equity
Restated Balance at 1 July 2018	482,024	402,310	1,671	-	464,823	4,277,934	5,255,636	10,884,399	(107,524)	10,776,875
Total comprehensive income										
Profit after tax	-	-	-	-	-	-	(315,698)	(315,698)	(89,604)	(405,302)
Other comprehensive income-net of tax	-	-	-	-	90,971	-	-	90,971	(28)	90,943
Total comprehensive income	-	-	-	-	90,971	-	(315,698)	(224,727)	(89,632)	(314,359)
Transaction with owners of the Company										
Share premium	-	-	-	-	-	-	-	-	-	-
Stock dividend for 2017-18	16,871	-	-	-	-	-	(16,871)	-	-	-
Cash dividend for 2017-18	-	-	-	-	-	-	(554,328)	(554,328)	(73,269)	(627,597)
Adjustment for transfer of shares in subsidiary	-	-	-	-	-	-	(46,283)	(46,283)	(3,517)	(49,800)
Total transactions with owners of the company	16,871	-	-	-	=	-	(617,482)	(600,611)	(76,786)	(677,397)
Balance at 31 March 2019	498,895	402,310	1,671	-	555,794	4,277,934	4,322,456	10,059,060	(273,942)	9,785,118

### **Advanced Chemical Industries Limited** Consolidated statement of cash flows Unaudited

	Figure	es in '000' Taka
	For the period up	to 3rd Quarter
	<b>July 2019</b>	July 2018
	to	to
	<b>March 2020</b>	<b>March 2019</b>
		Restated*
Cash flows from operating activities		
Cash receipts from customers and others	52,034,615	43,877,130
Cash paid to suppliers and employees	(48,472,652)	(43,695,005)
Cash generated from operating activities	3,561,962	182,125
Paid to WPPF	(76,289)	(111,903)
Finance costs paid	(2,823,435)	(2,245,035)
Income tax paid	(1,118,220)	(934,597)
•	(4,017,944)	(3,291,535)
Net cash from / (used in) operating activities * 16 (	(a) (455,981)	(3,109,410)
Cash flows from investing activities		
Acquisition of property, plant and equipment	(717,815)	(616,994)
Payments for capital work in progress	(1,191,311)	(2,241,351)
Sale proceeds from property, plant and equipment	5,429	872
Sale proceeds of Brands	-	540,300
Dividend received	302,556	2,856
Subsidiary amount included upon control established	-	11,586
Investment	(297,060)	(14,442)
Net cash used in investing activities	(1,898,201)	(2,317,173)
Cash flows from financing activities		
Inter-company debts received/(paid)	(41,174)	46,718
Dividend paid	(63,474)	(542,250)
Payment for lease liabilities	(341,692)	(269,339)
Paid as dividend to non-controlling interest	(67,291)	(72,054)
Short-term bank loan received/(paid)	2,521,844	5,220,961
Long-term bank loan received/(paid)	185,820	(274,397)
Net cash from financing activities	2,194,034	4,109,640
Net increase / (decrease) in cash and cash equivalents	(160,149)	(1,316,944)
Cash and cash equivalents at 1 July	(2,298,189)	(2,027,603)
Effect of movements in exchange rates on cash held	91	-
Cash and cash equivalents at 31 March	(2,458,247)	(3,344,547)
Closing balance represents		
Cash and cash equivalents	2,910,654	1,604,171
Bank overdraft	(5,368,901)	(4,948,719)
	(2,458,247)	(3,344,547)
Net operating cash flows per share (NOCFPS)	(7.95)	(54.20)
1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	( )	(/

<sup>\*</sup>See Note 16(a) for reconciliation of consolidated net operating cash flow. 10

# Advanced Chemical Industries Limited Notes to the financial statements as at and for the 3rd Quarter ended on 31 March 2020 Unaudited

### 1 Selected explanatory notes

These financial statements have been prepared in line with Accounting Policies as adopted in the preparation of financial statements for the year ended from 1 July 2018 to 30 June 2019. This interim financial report includes only those selected explanatory notes as were deemed appropriate for better understanding of unaudited financial statements.

Figures in '000' Taka

	rigules ili vvv Taka						
Property, plant and equipment	31 March 2020	<b>30 June 2019</b>					
	Taka	Taka					
Opening helenge	11 252 692	10,209,351					
		1,474,984					
±		(331,654)					
-		(1,460,908)					
Closing balance	10,518,560	9,891,774					
Consolidated property, plant and equipment							
Opening balance	29,600,056	25,838,936					
Additions	1,920,308	4,094,803					
Disposals	(10,765)	(333,683)					
Accumulated depreciation	(5,171,512)	(4,029,309)					
Closing balance	26,338,087	25,570,748					
Investments							
Investment in subsidiaries	1,674,736	1,674,761					
Investment in joint ventures	510,000	475,000					
Investment in associates	377,548	115,426					
Investment in shares	527,134	649,127					
Investment in FDR/ other deposits	3,917	3,917					
Impairment	(273,600)	(273,600)					
	2,819,735	2,644,630					
Inventories							
Raw materials	1,564,674	1,484,625					
Packing materials	466,039	391,495					
Work-in-process	202,770	239,377					
Finished goods	3,505,844	3,393,364					
Goods in transit	210,912	350,786					
Stores and spares	59,431	52,890					
Allowance for inventory	(540,229)	(436,463)					
	5,469,441	5,476,073					
	Opening balance Additions Disposals Accumulated depreciation Closing balance  Consolidated property, plant and equipment Opening balance Additions Disposals Accumulated depreciation Closing balance  Investments  Investment in subsidiaries Investment in joint ventures Investment in shares Investment in FDR/ other deposits Impairment  Inventories  Raw materials Packing materials Work-in-process Finished goods Goods in transit Stores and spares	Property, plant and equipment         31 March 2020					

		Figures in '000' Tal					
		31 March 2020	30 June 2019				
4 (a)	Consolidated inventories	Taka	Taka				
	Raw materials	3,660,087	3,458,798				
	Packing materials	587,661	664,577				
	Work-in-process	417,472	376,935				
	Finished goods	10,275,300	8,641,540				
	Goods in transit	554,757	777,285				
	Stores & spares	187,150	146,637				
	Allowance for inventory	(743,372)	(505,683)				
	Anowance for inventory	14,939,055	13,560,089				
5	Trade receivables						
	Debts due over six months	2,950,618	3,658,384				
	Debts due below six months	1,916,109	1,973,521				
	Provision for doubtful debts	(878,574)	(473,410)				
		3,988,152	5,158,496				
5 (a)	Consolidated trade receivables						
	Debts due over six months	4,349,448	4,731,896				
	Debts due below six months	10,271,200	9,897,773				
	Provision for doubtful debts	(1,223,600)	(802,503)				
		13,397,048	13,827,166				
6	Inter-company receivables						
	ACI Logistics Limited	5,916,461	4,334,973				
	ACI HealthCare Limited	4,544,197	3,483,486				
	ACI Foods Limited	2,895,626	2,829,893				
	Premiaflex Plastics Limited	2,651,201	1,830,157				
	ACI Formulations Limited	1,002,267	1,153,734				
	ACI Biotech Limited	570,769	482,721				
	ACI Agrolink Limited	561,867	395,148				
	Infolytx Bangladesh Limited	312,166	211,090				
	ACI Chemicals Limited	176,508	133,915				
	Asian Consumer Care (Pvt.) Limited	7,894	7,894				
	ACI Godrej Agrovet (Pvt. ) Limited	939	880				
	Tetley ACI (Bangladesh) Limited	457	39,930				
	Stochastic Logic Limited	91	1,851				
	Computer Technology Limited	30	30				
	Creative Communication	-	20,002				
		18,640,473	14,925,701				

		Fig 31 March 2020 Taka	Figures in '000' Taka 30 June 2019 Taka		
6 (a)	Consolidated inter-company receivables				
	Computer Technology Limited	30	30		
	Tetley ACI (Bangladesh) Limited	457	39,930		
	Asian Consumer Care (Pvt.) Limited	7,894	7,894		
	ACI Godrej Agrovet (Pvt. ) Limited	939	880		
	Stochastic Logic Limited	91	1,851		
		9,411	50,584		
7	Advances, deposits & prepayments				
	Loans and advances to staff and others	286,469	348,680		
	VAT current account	317,945	232,544		
	Deposits	204,346	191,108		
	Prepayments	45,601	32,064		
	Advance income tax	1,743,557	1,373,364		
		2,597,919	2,177,760		
7 (a)	Consolidated advances, deposits & prepayments				
	Loan and advance to staff and others	1,489,390	892,318		
	VAT current account	887,087	553,944		
	Advance for capital expenditure	8,084	8,578		
	Deposits	344,330	326,962		
	Prepayments	303,747	191,030		
	Advance income tax	4,831,945	3,710,743		
		7,864,583	5,683,575		
8	Employee benefits				
	Staff gratuity provision	895,713	798,775		
	Other long term employee benefits	143,879	142,454		
		1,039,592	941,229		
8 (a)	Consolidated employee benefits				
	Staff gratuity provision	1,189,768	1,025,318		
	Other long term employee benefits	155,903	153,554		
		1,345,672	1,178,872		

		Fig 31 March 2020 Taka	rres in '000' Taka 30 June 2019 Taka	
9	Long term borrowings			
	Long term bank loans	576,950	567,628	
		576,950	567,628	
9 (a)	Consolidated long term borrowings			
	Long term bank loans	8,264,998	8,079,177	
		8,264,998	8,079,177	
10	Loans and borrowings - short term			
	Short term loan	13,463,564	12,629,692	
	Current portion of long term loan	196,241	197,933	
		13,659,805	12,827,625	
10 (a)	Consolidated loans and borrowings - short term			
	Short term loan	25,360,430	22,842,587	
	Current portion of long term loan	4,425,331	4,421,329	
		29,785,761	27,263,917	
11	Inter company payables			
	ACI Motors Limited	2,960,053	3,313,312	
	ACI Salt Limited	1,168,512	692,844	
	ACI Pure Flour Limited	825,279	533,288	
	ACI Edible Oils Limited	60,737	10,286	
	Creative Communication Limited	2,096	4.540.520	
		5,016,677	4,549,730	

		Figures in '000' T			
		31 March 2020 Taka	<b>30 June 2019</b> Taka		
12	Other payables				
	Accruals	1,395,406	1,400,207		
	Advance from customers	100,070	35,498		
	Security money received from customers	99,089	139,695		
	Workers' profit participation fund	591,877	510,692		
	Unpaid dividend	536,874	101,453		
	Tax and VAT deducted at source	181,407	53,686		
	Employees welfare fund	279,053	274,234		
	Les Laboratories Servier	-	24,158		
	Rights share deposit to be refunded	564	564		
	Family day fund	4,716	4,315		
	Non-management staff provident fund	6,817	6,426		
	Unclaimed refund warrant - Zero Coupon Bonds	3,647	3,647		
	Payable for redemption of Zero Coupon Bonds	20,403	20,403		
	Management staff provident fund	14,199	22,371		
	Advertisement and promotional funds	16,159	17,736		
	Development funds	6,673	140,717		
	20 resopniem runus	3,256,954	2,755,802		
2 (a)	Consolidated other payables				
	Accruals	3,421,417	2,890,064		
	Advance from customers	342,894	204,393		
	Security money received from customers	152,932	202,427		
	Workers' profit participation fund	781,318	652,019		
	Unpaid dividend	554,661	113,263		
	Provident fund	14,865	22,371		
	Tax and VAT deducted at source	292,756	106,080		
	Employees welfare fund	319,693	290,523		
	Les Laboratories Servier	- · · · · · · · · · · · · · · · · · · ·	24,158		
	Rights share deposit to be refunded	564	564		
	Family day fund	4,716	4,315		
	Non-management staff provident fund	6,817	6,426		
	Unclaimed refund warrant - Zero Coupon Bonds	3,647	3,647		
	Payable for redemption of Zero Coupon Bonds	20,403	20,403		
	Creditors for capital expenditure	7,141	334		
	Advertisement and promotional funds	16,159	17,736		
	<u> •</u>				
	Development funds	6,673	140,717		

Figures in '000' Taka For the period up to 3rd Quarter July 2019 July 2018 to to March 2020 March 2019 Taka Taka 13 Revenue Pharmaceuticals 8,852,918 7,711,222 Animal Health 2,702,368 2,138,898 Consumer brands 4,013,079 4,766,916 Seeds 906,218 776,489 Fertilizer 727,281 932,377 Animal Genetics and others 55,481 17,257,345 16,325,901 13 (a) Consolidated revenue Gross sales 52,701,753 47,556,308 (842,608)(1,277,319)Inter-company sales 51,859,146 46,278,989 14 Cost of sales 5,508,860 5,048,323 Opening stock Purchase 8,095,389 8,402,689 13,604,250 13,451,012 (5,739,326)Closing stock (5,503,917)7,864,924 7,947,095 Manufacturing expenses 1,012,095 1,055,269 8,877,019 9,002,365 14 (a) Consolidated cost of sales Opening stock 12,237,772 11,272,404 Purchase 35,526,716 31,383,908 47,764,488 42,656,312 Closing stock (14,110,517)(11,878,255)33,653,971 30,778,057 2,573,904 2,084,974 Manufacturing expenses 36,227,875 32,863,031 Administrative, selling and distribution expenses Administrative expenses 320,391 373,588

663,833

5,596,374

6,580,598

644,079

5,940,574

4,922,908

Distribution expenses

Selling expenses

For the period up to 3rd Quarter July 2019 **July 2018** to to March 2020 March 2019 Taka Taka 15 (a) Consolidated operating expenses Administrative expenses 2,110,777 1,812,747 Distribution expenses 1,329,269 1,174,379 Selling expenses 7,828,187 9,201,536 12,641,582 10,815,314 Reconciliation of net operating cash flow 16 Profit after tax 1,212,798 670,324 Adjustment for non-cash items and others: - Depreciation and amoritisation 377,089 363,129 - Provisions 508,930 153,789 - Finance cost 82,543 25,217 - Tax Expense 61,865 (116,114)- Contribution to WPPF 46,193 (12,088)-Lease and other adjustments 93,293 115,274 Changes in: - Inventories (97,134)(503,443)- Trade and other receivables 115,267 (480,399)- Advances, deposits and prepayments (49,965)(61,300)- Trade and other payables, Employment benefits 305,544 571,134 2,922,014 459,933 Net cash from operating activities 16 (a) Reconciliation of Consolidated net operating cash flow Profit after tax (1,195,134)(405,302)Adjustment for non-cash items and others: - Depreciation and amoritisation 915,470 1,161,147 - Provisions 658,786 323,008 - Share of profit of equity accounted investees (209,033)(81,031)- Finance cost 702,226 18,135 - Tax Expense (208,762)(106,648)- Contribution to WPPF 88,610 2,873 -Lease and other adjustments 217,363 299,271 Changes in: - Inventories (1,616,656)(1,826,356)- Trade and other receivables (641,410)(3,456,762)- Advances, deposits and prepayments (1,059,807)(384,672)- Trade and other payables, Employment benefits 1,646,687 1,592,604 Net cash from operating activities (455,981)(3,109,410)

Figures in '000' Taka

17 Consolidated operating segments Please see Annexure A.

_ = == P === # TF TF TF Q == Q ====						
July 2019 to	July 2018 to					
March 2020	March 2019					
57,373	57,373					
(1,003,320)	(315,698)					
(17.49)	(5.50)					
7,967,122	9,580,018					
138.87	166.98					
(455,981)	(3,109,410)					
(7.95)	(54.20)					
	to March 2020  57,373  (1,003,320) (17.49)  7,967,122 138.87  (455,981)					

For the period up to 3rd Quarter

ACI Limited as a group has shown a decent revenue growth during the period. Despite having the growth in the Revenue and Gross Profit, the consolidated results up to 3rd quarter has demonstrated a loss compared to the SPLY mostly because of the increased Operating Expenses and Financing Cost. The consequential results of negative consolidated profit ultimately affected consolidated EPS and NAV per share. On the other hand, NOCFPS improved due to better cash collection during the period.

Figures have been rounded off to the nearest '000' Taka and previous period's figures have been rearranged to conform to current period's presentation.

### 20 Changes in accounting policies

The Group has applied IFRS 16 which has become initially applicable for the Group from 1 July 2019. As a result, the group has changed its accounting policies for lease contracts. The Group has applied IFRS 16 using retrospective approach. Therefore, comparative information have been restated.

Annexure-A
Consolidated operating segments

Figures in '000' Taka For the period up to 3rd Quarter from July 2019 to March 2020

					Reportab	ole Segment						Total		
Particulars	Pharmaceuticals	Animal	Consumer	Crop Care and	Motors	Pure Flour	Retail Chain	Salt	Foods	Premiaflex	HealthCare	reportable	Unallocated	Total
	Tharmaceuticals	Health	Brands	Public Health	Motors	Ture Piour	Retail Chain	San	roous	Treimanex	HealthCare	segments		
External revenue	8,852,918	2,702,368	3,853,558	2,006,806	9,536,906	3,687,487	8,551,798	1,514,069	3,760,684	3,062,815	1,717,158	49,246,567	2,612,579	51,859,146
Inter-segment revenue	-	-	409,921	-	3,316	28,398	23,559	49,026	35,816	190,693	-	740,728	101,880	842,608
Segment revenue	8,852,918	2,702,368	4,263,479	2,006,806	9,540,222	3,715,885	8,575,356	1,563,095	3,796,500	3,253,507	1,717,158	49,987,295	2,714,459	52,701,753
Depreciation and amortisation	243,255	22,550	60,528	24,482	46,502	24,861	164,514	39,070	47,287	192,653	206,278	1,071,980	89,167	1,161,147
Operating expenses	3,969,204	683,712	1,832,218	469,037	1,562,251	203,865	1,740,261	187,047	428,081	338,489	886,820	12,300,986	340,597	12,641,582
Finance cost / (income)	124,120	181,860	194,070	147,823	395,236	(46,482)	1,063,853	(31,109)	293,955	391,465	575,831	3,290,621	235,039	3,525,661
Segment profit/(loss) before tax	1,680,657	44,642	(752,941)	127,297	985,739	150,168	(1,156,455)	230,573	(81,765)	(305,496)	(1,451,941)	(529,522)	243,846	(285,676)
Segment assets at 31 Dec 2019	10,134,544	2,663,153	6,002,545	3,092,473	14,073,595	2,008,871	2,917,810	2,523,158	2,326,910	6,586,517	10,446,114	62,775,690	7,662,022	70,437,713
Segment liabilities at 31 Dec 2019	5,429,954	1,163,365	1,686,468	2,135,148	11,155,916	945,603	14,301,178	1,333,510	4,124,021	5,823,615	11,733,319	59,832,096	3,197,577	63,029,674

### For the period up to 3rd Quarter from July 2018 to March 2019

					Reportal	ole segment						Total		
Particulars	Pharmaceuticals	Animal Health	Consumer Brands	Crop Care and Public Health	Motors	Pure Flour	Retail Chain	Salt	Foods	Premiaflex	HealthCare	reportable segments	Unallocated	Total
External revenue	7,711,222	2,138,898	4,605,213	2,204,513	7,787,641	3,145,438	7,192,523	1,519,133	2,767,790	2,570,193	1,954,452	43,597,016	2,681,972	46,278,989
Inter-segment revenue	-	-	740,286	-	9,685	20,152	21,855	14,328	41,122	255,136	-	1,102,564	174,755	1,277,319
Segment revenue	7,711,222	2,138,898	5,345,499	2,204,513	7,797,326	3,165,590	7,214,378	1,533,461	2,808,912	2,825,329	1,954,452	44,699,580	2,856,728	47,556,308
Depreciation and amortisation	235,208	27,167	52,694	24,466	25,553	22,436	187,633	39,178	45,756	129,463	48,680	838,235	77,235	915,470
Operating expenses	3,640,462	631,761	1,581,498	503,872	1,023,176	198,719	1,617,544	172,344	376,639	261,470	531,710	10,539,194	276,120	10,815,314
Finance cost / (income)	83,230	143,100	83,774	140,615	241,519	(22,321)	894,244	(16,294)	254,637	185,165	31,451	2,019,119	385,591	2,404,711
Segment profit/(loss) before tax	1,330,265	(107,351)	(491,837)	175,342	884,721	18,738	(1,116,593)	137,619	(218,680)	(31,962)	(249,171)	331,089	86,816	417,905
Segment assets at 30 June 2019	8,657,395	3,032,942	7,505,815	3,395,285	11,084,826	1,717,547	2,780,116	2,006,585	2,105,367	6,258,937	9,163,034	57,707,850	7,504,547	65,212,397
Segment liabilities at 30 June 2019	4 006 837	1 151 045	1 531 673	2 347 992	8 791 366	740 796	12 945 023	955 502	3 806 545	5 178 550	9 176 316	50 631 647	5 352 015	55 983 662

<sup>\*</sup>Restated